Status:
RECRUITING
Safety and Efficacy of the CoolCryo System for Cardiac Cryoablation in the Treatment of Atrial Fibrillation
Lead Sponsor:
Medinice S.A.
Conditions:
Atrial Fibrillation, Paroxysmal or Persistent
Mitral Valve Disease
Eligibility:
All Genders
18+ years
Brief Summary
The study involves endocardial cryoablation of the left and/or right atrium of the heart using the CoolCryo system as an adjunct to mitral valve surgery, with the aim of eliminating atrial fibrillatio...
Detailed Description
An open-label, multi-centre, non-randomised study involving 16 patients, male and female, to evaluate the safety and efficacy of the CoolCryo system. The procedure with the medical device will be per...
Eligibility Criteria
Inclusion
- Written consent from the patient to participate in the study.
- age ≥18 years.
- patient qualified for mitral valve surgery (mitral valve plication or mitral valve replacement "with" or "without" left atrial appendage closure).
- a documented diagnosis of co-occurrence of paroxysmal or persistent atrial fibrillation (AF) since at least 3 months prior to surgery with exclusion of acute conditions.
Exclusion
- Lack of written consent from the patient to participate in the study.
- Failure to meet the inclusion criteria.
- Contraindications to the cryoablation procedure.
- Patient breastfeeding, pregnant or planning pregnancy within 6 months of study treatment.
- co-morbidities and/or conditions that may cause atrial fibrillation (uncompensated hyperthyroidism or hypothyroidism, acute infection, pheochromocytoma, significant dyselectrolitemia).
- significant calcification of the left atrium.
- Condition after previous cardiac surgery.
- significant left atrial enlargement (size greater than 10 cm on echocardiography in one of the projections performed). projection).
- the patient is currently a participant in another clinical trial.
- The patient is on active biological therapy.
- emergency surgery.
- Life expectancy \<12 months.
- Any circumstances that, in the opinion of the Investigator, may prevent the patient from participating in the study, limit the ability to perform the procedures outlined in the study protocol or place an unreasonable risk on the patient.
Key Trial Info
Start Date :
July 3 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2026
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06557616
Start Date
July 3 2024
End Date
June 30 2026
Last Update
September 23 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Antoni Jurasz University Hospital No. 1
Bydgoszcz, Poland, 85-094
2
Silesian Centre for Heart Diseases
Zabrze, Poland, 41-800